You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study

Article metrics

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial in Progress
1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study

 

Online download statistics by month:

Online download statistics by month: October 2023 to July 2025

AbstractFullPdf
Oct 2023800
Nov 2023136011
Dec 20236104
Jan 20247003
Feb 20244003
Mar 20244001
Apr 20241402
May 20242204
Jun 202432012
Jul 20249807
Aug 20241604
Sep 20242201
Oct 20243003
Nov 20245803
Dec 20241004
Jan 20252102
Feb 2025003
Mar 2025004
Apr 2025002
May 2025001
Jun 2025103
Jul 2025001
Total679078